Boehringer’s Trajenta Enters China As DPP-4 Latecomer, But Playing Field Still Level
This article was originally published in PharmAsia News
Boehringer Ingelheim’s first diabetes product, Trajenta, has been approved in China. It enters China as the fourth DPP-4, but it may not have far to catch up given the reimbursement landscape.
You may also be interested in...
Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.